Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 1c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea